An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines

International Braz J Urol

Volumn 35, Issue 3, 2009, Pages 354-360

  Piantino, Camila B ^a,b   Salvadori, Fernanda A ^a,b   Ayres, Pedro P ^a,b   Kato, Raphael B ^a,b   Srougi, Victor ^a,b   Leite, Katia R ^a,b,c   Srougi, Miguel ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c Genoa Biotechnology   (Brazil)

Author keywords

Apoptosis; Curcuma longa; Curcumin; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN;

APOPTOSIS; ARTICLE; DRUG EFFECT; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CURCUMIN; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 77949333956     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382009000300012     Document Type: Article

References (26)

1. Available at: http/www.inca.gov.br.
2. Moyad MA: Alternative therapies for advanced prostate cancer. What should I tell my patients? Urol Clin North Am. 1999; 26: 413-7.
3. Denis L, Morton MS, Griffiths K: Diet and its preventive role in prostatic disease. Eur Urol. 1999; 35: 377-87.
4. Hergenhahn M, Soto U, Weninger A, Polack A, Hsu CH, Cheng AL, et al.: The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells. Mol Carcinog. 2002; 33: 137-45.
5. Kato K, Ito H, Kamei K, Iwamoto I: Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperones. 1998; 3: 152-60.
6. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, et al.: Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem. 2000; 275: 10405-12.
7. Woo MS, Jung SH, Kim SY, Hyun JW, Ko KH, Kim WK, et al.: Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun. 2005; 335: 1017-25.
8. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21: 2895-900.
9. Orlowski RZ, Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002; 8: 385-9.
10. Skommer J, Wlodkowic D, Pelkonen J: Cellular foundation of curcumin-induced apoptosis in follicular lymphoma cell lines. Exp Hematol. 2006; 34: 463-74.
11. Schmelz M, Cress AE, Barrera J, McDaniel KM, Davis TL, Fuchs L, et al.: PEAZ-1: a new human prostate neoplastic epithelial cell line. Prostate. 2001; 48: 79-92. Erratum in: Prostate. 2004; 61: 375.
12. Erratum: Monika Schmelz, Anne E. Cress, Jean Barrera, Kathy M. McDaniel, Tracy L. Davis, Laura Fuchs, Bruce L. Dalkin, Raymond B. Nagle. PEAZ-1: A new human prostate neoplastic epithelial cell line. Prostate 2001;48:79-92. Prostate. 2004; 61: 375.
13. Rhim JS: In vitro human cell culture models for the study of prostate cancer. Prostate Cancer Prostatic Dis. 2000; 3: 229-235.
14. Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, et al.: A novel neoplastic primary tumor-derived human prostate epithelial cell line. Int J Oncol. 2003; 22: 1311-7.
15. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15: 356-62.
16. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275: 1943-7.
17. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991; 51: 4716-20.
18. Dorai T, Gehani N, Katz A: Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol. 2000; 4: 1-6.
19. Stoner GD, Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl. 1995; 22: 169-80.
20. Kuttan R, Bhanumathy P, Nirmala K, George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985; 29: 197-202.
21. Kuo ML, Huang TS, Lin JK: Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta. 1996; 1317: 95-100.
22. Khar A, Ali AM, Pardhasaradhi BV, Begum Z, Anjum R: Antitumor activity of curcumin is mediated through the induction of apoptosis in AK-5 tumor cells. FEBS Lett. 1999; 445: 165-8.
23. Scott DW, Loo G: Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis. 2004; 25: 2155-64.
24. Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23: 363-98.
25. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S: Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999; 93: 152-61.
26. Shankar S, Srivastava RK: Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol. 2007; 30: 905-18.